Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds-News

China Biologic Products, Inc. (CBPO): Warburg Pincus Sells Shares to Underwriter

Published on March 8, 2016 at 9:15 pm by Meena Krishnamsetty in Hedge Funds, News
Page 1 of 17
Next >>

Warburg Pincus has just filed a Form 13D with the SEC, updating the regulatory body on the latest pertinent information related to its position in China Biologic Products Inc (NASDAQ:CBPO). The activist filing reveals that the investment firm has sold over half of its stake in the company since the end of 2015, when it held 8.34 million shares. The firm now owns 4.09 million shares of the issuer.

Item 4 of the filing was updated with the following information related to the recent large sale of shares:

“On March 4, 2016, the Underwriter notified the Funds of its election to exercise the option to purchase additional Shares from the Funds in full.

On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.”

Shares of CBPO currently trade at $109.28 and are down by 23% this year.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
WP X Biologics 0 3,112,920 0 3,112,920 3,112,920 11.7%
Warburg Pincus Private Equity X 0 3,960,496 0 3,960,496 3,960,496 14.9%
Warburg Pincus X Partners 0 126,704 0 126,704 126,704 0.5%
Warburg Pincus X 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus X GP 0 4,087,200 0 4,087,200 4,087,200 15.4%
WPP GP 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus Partners 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus Partners GP 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus Co 0 4,087,200 0 4,087,200 4,087,200 15.4%
Warburg Pincus 0 4,087,200 0 4,087,200 4,087,200 15.4%
Charles R. Kaye 0 4,087,200 0 4,087,200 4,087,200 15.4%
Joseph P. Landy 0 4,087,200 0 4,087,200 4,087,200 15.4%

Page 1 of 17 SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 15)*

China
Biologic Products, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

16938C106

(CUSIP Number)

Robert B. Knauss

Managing Director and General Counsel

Warburg Pincus LLC

450
Lexington Avenue

New York, NY 10017

(212) 878-0600

With a copy to:

Weiheng Chen, Esq.

Wilson Sonsini Goodrich & Rosati, P.C.

Suite 1509, 15/F, Jardine House

1 Connaught Place, Central

Hong Kong

+(852) 3972
4955

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 7, 2016

(Date of
Event Which Requires Filing of This Statement)

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box.  ¨

Follow China Biologic Products Inc. (NASDAQ:CBPO)
Page 1 of 17
Next >>

Related Insider Monkey Articles
Is China Biologic Products Inc (CBPO) A Good Stock To Buy?InterMune Inc (ITMN): Hedge Funds Aren't Crazy About It, Insider Sentiment...
GL Partners Adds to Position in SciClone Pharmaceuticals; Reveals New Stake...Should You Follow This Investor Into His Biotech Picks?
Hedge Funds Are Dumping Dendreon Corporation (DNDN)Is Achillion Pharmaceuticals, Inc. (ACHN) Going to Burn These Hedge Funds?